← Leaderboards
Michael J Kelley
Duke University
$3,319,783
Attributed
$3,319,783
Total exposure
7
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $500.5K · FY2005–24$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$3,319,783 · 5
VA$0 · 2
By mechanism
U01$2,251,445 · 1
R21$592,799 · 1
R01$442,798 · 1
M01$32,741 · 2
I01$0 · 2
Top collaborators
- Kara N Maxwell2 shared
- Saiju Pyarajan2 shared
Most similar at Duke University
Same institution · by research overlap
- Robert Mullan Cook-Deegan$6,545,004
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectGenomicsVeteransTumorMolecularBaseCharacteristicsPathway InteractionsVariantGeneticSuccessBiomarkerMutationMalignant NeoplasmsGene ExpressionPatient Oriented ResearchBortezomibClinical PracticeBiologyAccelerationChordomaClinical CareCell Growth
Grant awards (18)
Mutational processes underlying tumor development in United States Veterans$0
I01 · FY2024 · VA
Mutational processes underlying tumor development in United States Veterans$0
I01 · FY2024 · VA
Genetic Analysis of Chordoma$0
I01 · FY2012 · VA · contact PI
Genetic Analysis of Chordoma$0
I01 · FY2011 · VA · contact PI
Genetic Analysis of Chordoma$0
I01 · FY2011 · VA · contact PI
Genetic Analysis of Chordoma$0
I01 · FY2009 · VA · contact PI
Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers$442,543
U01 · FY2006 · CA · contact PI
Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers$477,498
U01 · FY2005 · CA
PILOT PHASE II RESEARCH STUDY OF EF5 TO MEASURE TUMOR HYPOXIA$16,738
M01 · FY2005 · RR
PHASE I STUDY OF GEFITINIB (IRESSA?) AND CELECOXIB IN FORMER SMOKERS WITH ADVAN$6,276
M01 · FY2005 · RR
Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers$465,839
U01 · FY2004 · CA
Phase II Research Study of EF5 to Measure Tumor Hypoxia$9,727
M01 · FY2004 · RR
Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers$454,498
U01 · FY2003 · CA
Measurement of Hypoxia in Non Small Cell Lung Carcinoma$296,164
R21 · FY2003 · CA
Phase I/II Trial of ZD1839 and Celecoxib in Ex-Smokers$411,067
U01 · FY2002 · CA
Measurement of Hypoxia in Non Small Cell Lung Carcinoma$296,635
R21 · FY2002 · CA
GENETIC ANALYSIS OF HEREDITARY MACROTHROMBOCYTOPENIAS$220,513
R01 · FY2002 · HL
GENETIC ANALYSIS OF HEREDITARY MACROTHROMBOCYTOPENIAS$222,285
R01 · FY2001 · HL